Literature DB >> 12019179

Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor.

Gisele Höpfl1, Roland H Wenger, Urs Ziegler, Thomas Stallmach, Olivier Gardelle, Roger Achermann, Melanie Wergin, Barbara Kaser-Hotz, H Mark Saunders, Kaye J Williams, Ian J Stratford, Max Gassmann, Isabelle Desbaillets.   

Abstract

In tumors, rapid cell proliferation associated with deficient vascularization leads to areas of hypoxia. Tumor hypoxia has direct consequences on clinical and prognostic parameters and is a potential therapeutic target. The hypoxic response depends critically on hypoxia-inducible factor-1alpha (HIF-1alpha) in pathological (e.g., tumorigenesis) as well as physiological (e.g., development and wound healing) processes. By s.c. injection of HIF-1alpha(-/-) embryonic stem (ES) cells in nude mice, we were able to demonstrate the role of HIF-1alpha in cell differentiation of teratocarcinomas. HIF-1alpha(+/+) tumors grow fast and preferentially form neuronal tissue, whereas HIF-1alpha(-/-) tumors show delayed growth and favorably form mesenchyme-derived tissue. Mixing wild-type and HIF-1alpha(-/-) ES cells in the same tumor at a ratio as low as 1:100, we showed that HIF-1alpha(+/+) cells can rescue the growth of mixed tumors although these tumors are not significantly different phenotypically or genotypically from the original HIF-1alpha(-/-) tumors. Interestingly, these results are not restricted to teratocarcinomas: they were confirmed with mixtures of Hepa1/Hepa1C4 cells (where HIF-1beta is mutated), demonstrating that growth changes are not related to differences in differentiation observed within teratocarcinomas. We also showed that despite lower mRNA expression, vascular endothelial growth factor protein status in HIF-1alpha(-/-) and mixed tumors does not significantly differ from the HIF-1alpha(+/+) tumors. Moreover, we demonstrated that tumor vascularization remains proportional to vascular endothelial growth factor protein levels, but that hypoxic up-regulation of this growth factor is not the decisive factor influencing tumor growth. Differences in levels of apoptosis are not responsible for alteration in growth because poly(ADP-ribose) polymerase cleavage, a hallmark of the apoptotic process, was similar in HIF-1alpha(+/+), HIF-1alpha(-/-), and mixed tumors. Our data demonstrate that the HIF-1alpha-dependent response of a few cells is capable of sustaining the growth of the whole tumor, probably through the secretion of factors up-regulated under low oxygen conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019179

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets.

Authors:  Kim Cheng; Kenneth Ho; Rebecca Stokes; Christopher Scott; Sue Mei Lau; Wayne J Hawthorne; Philip J O'Connell; Thomas Loudovaris; Thomas W Kay; Rohit N Kulkarni; Terumasa Okada; Xiaohui L Wang; Sun Hee Yim; Yatrik Shah; Shane T Grey; Andrew V Biankin; James G Kench; D Ross Laybutt; Frank J Gonzalez; C Ronald Kahn; Jenny E Gunton
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

2.  Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts.

Authors:  Yu-Dong Zhou; Yong-Pil Kim; Xing-Cong Li; Scott R Baerson; Ameeta K Agarwal; Tyler W Hodges; Daneel Ferreira; Dale G Nagle
Journal:  J Nat Prod       Date:  2004-12       Impact factor: 4.050

3.  Defective brain development in mice lacking the Hif-1alpha gene in neural cells.

Authors:  Shuhei Tomita; Masaki Ueno; Masami Sakamoto; Yuki Kitahama; Masaaki Ueki; Nobuhiro Maekawa; Haruhiko Sakamoto; Max Gassmann; Ryoichiro Kageyama; Natsuo Ueda; Frank J Gonzalez; Yousuke Takahama
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

4.  The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia.

Authors:  Pengfei Zhu; Yanxia Ning; Liangqing Yao; Mo Chen; Congjian Xu
Journal:  J Exp Clin Cancer Res       Date:  2010-09-10

5.  Hypoxia-inducible factor-1α enhances the malignant phenotype of multicellular spheroid HeLa cells in vitro.

Authors:  Xun Tian; Wei Wang; Qinghua Zhang; Liangping Zhao; Junchen Wei; Hui Xing; Yuping Song; Shixuan Wang; Ding Ma; Li Meng; Gang Chen
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

6.  Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.

Authors:  Fiona A Mack; W Kimryn Rathmell; Andrew M Arsham; James Gnarra; Brian Keith; M Celeste Simon
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

Review 7.  Mammalian target of rapamycin (mTOR) Inhibitors.

Authors:  Janice P Dutcher
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

8.  Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1beta) activity is required more during early than late tumor growth.

Authors:  S Shi; D Y Yoon; K Hodge-Bell; S Huerta-Yepez; O Hankinson
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

Review 9.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Drug Targets       Date:  2006-03       Impact factor: 3.465

10.  Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer.

Authors:  Hongzhang Li; Jiaoe Chen; Wanli Zen; Xuehua Xu; Yanjun Xu; Qiang Chen; Tiangan Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.